Assenagon Asset Management
CLDX icon

Assenagon Asset Management’s Celldex Therapeutics CLDX Stock Holding History

Assenagon Asset Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$29.3M Buy
788,696
+642,171
+438% +$20.7M 0.04% 325
2026
Q1 		$4.65M Buy
+146,525
New +$3.99M 0.01% 602
2024
Q4 		– Sell
-20,946
Closed -$712K – 1351
2024
Q3 		$712K Sell
20,946
-118,216
-85% -$4.5M ﹤0.01% 1188
2024
Q2 		$5.15M Buy
139,162
+48,231
+53% +$1.82M 0.01% 628
2024
Q1 		$3.82M Buy
+90,931
New +$3.73M 0.01% 672

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Assenagon Asset Management's CLDX Position: Q2 2026 in Review

Assenagon Asset Management increased its Celldex Therapeutics (CLDX) stake by 438% in Q2 2026, buying an estimated $20.7M and bringing the position to 788,696 shares worth $29.3M. The position accounts for 0.04% of the portfolio, ranked #325.

Assenagon Asset Management first reported a position in CLDX in Q1 2024 and has held it in 5 quarters since. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Assenagon Asset Management held 788,696 shares of Celldex Therapeutics worth $29.3M as of Q2 2026.
  • Assenagon Asset Management bought 642,171 Celldex Therapeutics shares in Q2 2026, an estimated $20.7M.
  • Celldex Therapeutics made up 0.04% of Assenagon Asset Management's portfolio in Q2 2026, its #325 holding.
  • Assenagon Asset Management first reported a position in Celldex Therapeutics in Q1 2024 and has held it in 5 quarters since.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.